These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29736816)

  • 1. Pre-exposure Prophylaxis for HIV Infection in the Older Patient: What can be Recommended?
    Franconi I; Guaraldi G
    Drugs Aging; 2018 Jun; 35(6):485-491. PubMed ID: 29736816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
    Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.
    Mugwanya KK; Baeten JM
    Expert Opin Drug Saf; 2016; 15(2):265-73. PubMed ID: 26634852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
    Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
    Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
    Krakower DS; Mayer KH
    Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France.
    Noret M; Balavoine S; Pintado C; Siguier M; Brun A; Bauer R; Loze B; Leplatois A; Aslan A; Moudachirou K; Delaugerre C; Rozenbaum W; Molina JM
    AIDS; 2018 Sep; 32(15):2161-2169. PubMed ID: 30212403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
    Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M
    HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.
    Tetteh RA; Yankey BA; Nartey ET; Lartey M; Leufkens HG; Dodoo AN
    Drug Saf; 2017 Apr; 40(4):273-283. PubMed ID: 28130774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
    Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
    Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
    Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Trigeminal Neuralgia Associated with Initiation of Emtricitabine/Tenofovir for HIV Pre-Exposure Prophylaxis.
    Van Slyke L; Scott M
    J Int Assoc Provid AIDS Care; 2018; 17():2325958218760846. PubMed ID: 29534653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Parikh UM; Mellors JW
    Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV Preexposure Prophylaxis: A Review.
    Riddell J; Amico KR; Mayer KH
    JAMA; 2018 Mar; 319(12):1261-1268. PubMed ID: 29584848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabine.
    Siguier M; Mera R; Pialoux G; Ohayon M; Cotte L; Valin N; Ghosn J; Cua E; Pintado C; Chas J; Barriere G; Durand F; Molina JM
    J Antimicrob Chemother; 2019 Sep; 74(9):2752-2758. PubMed ID: 31219561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
    Adams JL; Shelley K; Nicol MR
    Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions.
    Hodges-Mameletzis I; Fonner VA; Dalal S; Mugo N; Msimanga-Radebe B; Baggaley R
    Drugs; 2019 Aug; 79(12):1263-1276. PubMed ID: 31309457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT
    JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
    Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
    BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement.
    ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Curry SJ; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
    JAMA; 2019 Jun; 321(22):2203-2213. PubMed ID: 31184747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection.
    Traeger MW; Cornelisse VJ; Asselin J; Price B; Roth NJ; Willcox J; Tee BK; Fairley CK; Chang CC; Armishaw J; Vujovic O; Penn M; Cundill P; Forgan-Smith G; Gall J; Pickett C; Lal L; Mak A; Spelman TD; Nguyen L; Murphy DA; Ryan KE; El-Hayek C; West M; Ruth S; Batrouney C; Lockwood JT; Hoy JF; Hellard ME; Stoové MA; Wright EJ;
    JAMA; 2019 Apr; 321(14):1380-1390. PubMed ID: 30964528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.